Emerging research links gut microbiota and the estrobolome to breast cancer development, exploring how oral endocrine therapy alters microbial composition and may influence recurrence risk.
Emerging research links gut microbiota and the estrobolome to breast cancer development, exploring how oral endocrine therapy alters microbial composition and may influence recurrence risk.